Eurofins Genomics has adopted Olink technology to advance proteomics research and accelerate its precision medicine programmes.
The collaboration is designed to bolster the company’s offerings in the fields of research, population health, and regulated clinical trials.
Olink Explore HT is the company’s latest solution for high-throughput proteomics, allowing scientists to accurately measure over 5,300 proteins using only 2µl of sample.
Eurofins Genomics will extend its multi-omic offering to facilitate the discovery and validation of protein biomarkers across biological pathways and sample matrices through the use of the Olink platform.
Eurofins Genomics will begin applying Olink Explore in three areas: expanding proteogenomics to enable deeper insight into the basis of disease, increasing biomarker discovery for pre-clinical development and clinical trials, and providing high throughput proteomic analysis for population-scale health studies.